Evidence map›Paper›PMID 20238337›Full record

SynthesisThe Cochrane database of systematic reviews2010

Anticonvulsants for alcohol withdrawal.

Silvia Minozzi, Laura Amato, Simona Vecchi, Marina Davoli

Registry-linked trialOpen access · greenAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in The Cochrane database of systematic reviews, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01379469 (A Preliminary Study of the Efficacy and Safety of Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency), which is not on this map. Cited by 35 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 13 pooled it
6.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01379469 phase2terminatednot on this mapstarted 2012, after this paper: background citation

A Preliminary Study of the Efficacy and Safety of Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency

TypeinterventionalSponsorWashington University School of MedicineRan2012 to 2017Enrolled20ConditionsAlpha-1-antitrypsin Deficiency, Liver CirrhosisArmsDrug-Carbamazepine (Tegretol XR), Carbamazepine (Tegretol XR) Placebo
3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 13 syntheses or guidelines pooled it, 140 citations in OpenAlex.

  1. Baclofen for alcohol use disorder.The Cochrane database of systematic reviews · 2023
    Pooled it
  2. Pooled it
  3. Alcohol intake reduction for controlling hypertension.The Cochrane database of systematic reviews · 2020
    Pooled it
  4. Baclofen for alcohol withdrawal.The Cochrane database of systematic reviews · 2019
    Pooled it
  5. Guideline
  6. Baclofen for alcohol use disorder.The Cochrane database of systematic reviews · 2018
    Pooled it
  7. Pooled it
  8. Baclofen for alcohol withdrawal.The Cochrane database of systematic reviews · 2017
    Pooled it
  9. Antipsychotic medications for cocaine dependence.The Cochrane database of systematic reviews · 2016
    Pooled it
  10. Pooled it
  11. Anticonvulsants for alcohol dependence.The Cochrane database of systematic reviews · 2014
    Pooled it
  12. Pooled it
  13. Benzodiazepines for alcohol withdrawal.The Cochrane database of systematic reviews · 2010
    Pooled it
  14. Article
  15. Long-term outcome of alcohol withdrawal seizures.European journal of neurology · 2024
    Article
  16. Article
  17. Article
  18. Article
  19. Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater · 2020
    Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Silvia MinozziDepartment of Epidemiology, ASL RM/E, Via di Santa Costanza, 53, Rome, Italy, 00198.
Laura Amato
Simona Vecchi
Marina Davoli
Azienda Sanitaria Locale Roma 3 · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlcohol abuse and dependence represents a most serious health problem worldwide with major social, interpersonal and legal interpolations. Besides benzodiazepines, anticonvulsants are often used for the treatment of alcohol withdrawal symptoms. Anticonvulsants drugs are indicated for the treatment of alcohol withdrawal syndrome, alone or in combination with benzodiazepine treatments. In spite of the wide use, the exact role of the anticonvulsants for the treatment of alcohol withdrawal has not yet bee adequately assessed.

objectivesTo evaluate the effectiveness and safety of anticonvulsants in the treatment of alcohol withdrawal. SEARCH STRATEGY: We searched Cochrane Drugs and Alcohol Group' Register of Trials (December 2009), PubMed, EMBASE, CINAHL (1966 to December 2009), EconLIT (1969 to December 2009). Parallel searches on web sites of health technology assessment and related agencies, and their databases. SELECTION CRITERIA: Randomized controlled trials (RCTs) examining the effectiveness, safety and overall risk-benefit of anticonvulsants in comparison with a placebo or other pharmacological treatment. All patients were included regardless of age, gender, nationality, and outpatient or inpatient therapy. DATA COLLECTION AND ANALYSIS: Two authors independently screened and extracted data from studies. MAIN

resultsFifty-six studies, with a total of 4076 participants, met the inclusion criteria. Comparing anticonvulsants with placebo, no statistically significant differences for the six outcomes considered.Comparing anticonvulsant versus other drug, 19 outcomes considered, results favour anticonvulsants only in the comparison carbamazepine versus benzodiazepine (oxazepam and lorazepam) for alcohol withdrawal symptoms (CIWA-Ar score): 3 studies, 262 participants, MD -1.04 (-1.89 to -0.20), none of the other comparisons reached statistical significance.Comparing different anticonvulsants no statistically significant differences in the two outcomes considered.Comparing anticonvulsants plus other drugs versus other drugs (3 outcomes considered), results from one study, 72 participants, favour paraldehyde plus chloral hydrate versus chlordiazepoxide, for the severe-life threatening side effects, RR 0.12 (0.03 to 0.44). AUTHORS'

conclusionsResults of this review do not provide sufficient evidence in favour of anticonvulsants for the treatment of AWS. There are some suggestions that carbamazepine may actually be more effective in treating some aspects of alcohol withdrawal when compared to benzodiazepines, the current first-line regimen for alcohol withdrawal syndrome. Anticonvulsants seem to have limited side effects, although adverse effects are not rigorously reported in the analysed trials.

Indexed as

Alcohol Withdrawal DeliriumAlcohol Withdrawal SeizuresAnticonvulsantsHumansRandomized Controlled Trials as TopicAnticonvulsants

Identifiers

PMID20238337
PMCPMC12318632
OpenAlexW1794118991

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.